Stay updated with breaking news from Sonja Nelson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
B. Riley lowered shares of Ambrx Biopharma (NYSE:AMAM – Free Report) from a buy rating to a neutral rating in a research note released on Tuesday, MarketBeat Ratings reports. B. Riley currently has $28.00 price objective on the stock, up from their previous price objective of $26.00. A number of other analysts have also weighed […]
B. Riley downgraded shares of Ambrx Biopharma (NYSE:AMAM – Free Report) from a buy rating to a neutral rating in a research report report published on Tuesday, Marketbeat Ratings reports. B. Riley currently has $28.00 price objective on the stock, up from their previous price objective of $26.00. Several other brokerages have also recently commented […]
Commodore Capital LP lowered its position in shares of Ambrx Biopharma Inc. (NYSE:AMAM – Free Report) by 33.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,175,000 shares of the company’s stock after selling 1,628,447 shares during the period. […]
Commodore Capital LP reduced its stake in shares of Ambrx Biopharma Inc. (NYSE:AMAM – Free Report) by 33.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,175,000 shares of the company’s stock after selling 1,628,447 shares during the quarter. Ambrx Biopharma comprises about […]
Ambrx Biopharma Inc. (NYSE:AMAM – Free Report) – Analysts at Cantor Fitzgerald cut their FY2023 earnings per share estimates for Ambrx Biopharma in a note issued to investors on Tuesday, November 14th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will post earnings of ($1.37) per share for the year, down from their […]